Dark

Check out our API

ALLR
Allarity Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Sep 18, 2026 9:45:46 AM EDT

1.17USD+0.862%(+0.01)20,005

0.9800Bid 1.34Ask 0.36Spread

Pre-market

Sep 18, 2026 9:22:30 AM EDT

1.13USD-2.586%(-0.03)11,642

After-hours

Sep 17, 2026 4:16:30 PM EDT

1.17USD+0.862%(+0.01)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

08:03AM EST Allarity Therapeutics, Oncoheroes Biosciences Sign Agreements To Advance Pediatric Cancer Development Of Dovitinib And Stenoparib Benzinga

08:00AM EST Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements GlobeNewswire Inc

Dec 22, 2021

08:22AM EST Allarity Therapeutics Submits New Drug Application To The FDA For Dovitinib For Third-Line Treatment Of Renal Cell Carcinoma Benzinga

Nov 11, 2021

02:30AM EST Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, includingtesting ofalpha variant B.1.1.7(British variant),beta variantB.1351 (South African variant), andgamma variant P.1 (Brazilian variant). GlobeNewswire Inc

Nov 5, 2021

04:49PM EDT U.S. SEC Issues Order Declaring Allarity Therapeutics GlobeNewswire Inc

Sep 16, 2021

04:00AM EDT -- Patient selection using DRP score of 50% resulted in a median survival of 15.0 month -- Patient selection using DRP score of 67% resulted in a median survival of 20.6 months GlobeNewswire Inc

Aug 5, 2021

07:00AM EDT Allarity Therapeutics oral PARP inhibitor, GlobeNewswire Inc

Jul 26, 2021

02:30AM EDT -- Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program GlobeNewswire Inc

Jul 5, 2021

02:00PM EDT -- Administrative acceptance review notification of pre-market approval (PMA)application is first step in multi-stepprocess conducted by the FDA -- The PMA is submitted in support of an imminent new drug application (NDA) for dovitinib GlobeNewswire Inc

Share